Free Trial
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$3.50 +0.23 (+7.03%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$3.48 -0.02 (-0.57%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Key Stats

Today's Range
$3.26
$3.54
50-Day Range
$3.06
$3.59
52-Week Range
$2.30
$4.73
Volume
1.44 million shs
Average Volume
1.06 million shs
Market Capitalization
$663.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Remove Ads

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

ABUS MarketRank™: 

Arbutus Biopharma scored higher than 28% of companies evaluated by MarketBeat, and ranked 832nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    5.26% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 13.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.26% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 13.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arbutus Biopharma has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Arbutus Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Arbutus Biopharma is held by insiders.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Chardan Capital Issues Optimistic Forecast for ABUS Earnings
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 4.1% on Strong Earnings
Trump's 100-Day Plan Triggers Global Retaliation
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
Arbutus Biopharma: A Wing And A Prayer
Arbutus Biopharma reports FY24 EPS (38c), consensus (55c)
Arbutus Biopharma reduced workforce by 57%
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $3.27 at the beginning of the year. Since then, ABUS stock has increased by 7.0% and is now trading at $3.50.
View the best growth stocks for 2025 here
.

Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, March, 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $1.57 million for the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative trailing twelve-month return on equity of 68.18%.

Arbutus Biopharma's top institutional shareholders include Whitefort Capital Management LP (6.99%), Vanguard Group Inc. (4.74%), Two Seas Capital LP (4.61%) and Two Seas Capital LP (4.61%).
View institutional ownership trends
.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
3/27/2025
Today
3/30/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABUS
Employees
90
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+57.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-72,850,000.00
Net Margins
-1,137.65%
Pretax Margin
-1,137.65%

Debt

Sales & Book Value

Annual Sales
$6.17 million
Price / Cash Flow
N/A
Book Value
$0.63 per share
Price / Book
5.56

Miscellaneous

Free Float
181,912,000
Market Cap
$663.22 million
Optionable
Optionable
Beta
1.93

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners